Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Alan N Baer"'
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0239769 (2020)
PurposeTo report the significance of extraglandular ocular involvement and long-term systemic morbidity and mortality in primary Sjögren's Syndrome (SS).MethodsThis retrospective, longitudinal cohort study included consecutive patients with primary
Externí odkaz:
https://doaj.org/article/40a88fb224f147529754bed81d1b394e
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 19, Iss , Pp 100790- (2020)
Purpose: To report the case of a patient who presents with multiple progressive ocular diseases who is diagnosed with concurrent primary Sjögren's syndrome and isolated ocular sarcoidosis. Observation: A 60-year-old woman was referred for dry eye di
Externí odkaz:
https://doaj.org/article/92dce015412c49babc6f9f59a211df9d
Autor:
Joel J. Credle, Jonathan Gunn, Puwanat Sangkhapreecha, Daniel R. Monaco, Xuwen Alice Zheng, Hung-Ji Tsai, Azaan Wilbon, William R. Morgenlander, Andre Rastegar, Yi Dong, Sahana Jayaraman, Lorenzo Tosi, Biju Parekkadan, Alan N. Baer, Mario Roederer, Evan M. Bloch, Aaron A. R. Tobian, Israel Zyskind, Jonathan I. Silverberg, Avi Z. Rosenberg, Andrea L. Cox, Tom Lloyd, Andrew L. Mammen, H. Benjamin Larman
Publikováno v:
Nat Biomed Eng
Pathogenic autoreactive antibodies that may be associated with life-threatening Coronavirus disease 2019 (COVID-19) remain to be identified. Here we show that self-assembled genome-scale libraries of full-length proteins covalently coupled to unique
Autor:
Michael T. Brennan, Alan N. Baer
Publikováno v:
Oral Diseases.
Autor:
Monisha Billings, DDS, MPH, PhD, Bruce A. Dye, DDS, MPH, Timothy Iafolla, DMD, MPH, Alan N. Baer, MD, Margaret Grisius, DDS, Ilias Alevizos, DMD, PhD
Publikováno v:
EBioMedicine, Vol 12, Iss C, Pp 270-279 (2016)
Background: Xerostomia is a chief complaint of patients with Sjögren's syndrome (SS). However, newer proposals for SS classification remove xerostomia and hyposalivation from the criteria list. Given these developments and the importance of patient-
Externí odkaz:
https://doaj.org/article/bf49d8b316114e449862b2856dba1ce1
Publikováno v:
J Rheumatol
ObjectiveSjögren syndrome (SS) has a significant impact on health-related quality of life (HRQOL). We sought to evaluate how the Patient Reported Outcome Measurement Information System (PROMIS) domains in SS may supplement the European League Agains
Autor:
Jelle Vehof, Michele Bombardieri, Jacques-Eric Gottenberg, Simon J Bowman, Gwenny M Verstappen, Marleen Nys, Neelanjana Ray, Liseth de Wolff, Frans G. M. Kroese, Elena Pontarini, Jolien F van Nimwegen, Hendrika Bootsma, Alan N. Baer, Suzanne Arends, Arjan Vissink, Renaud Felten
Publikováno v:
The Lancet Rheumatology, 3(8), E553-E562. Elsevier
Summary Background Recent randomised controlled trials (RCTs) in primary Sjogren's syndrome used the European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) as their primary endpoint. Given the heterogeneous and
Publikováno v:
Arthritis Care Res (Hoboken)
Objective To evaluate the safety and utility of core needle biopsy (CNB) for diagnosis of salivary gland lymphoma in Sjogren's syndrome (SS). Methods We analyzed data from consecutive SS patients who underwent ultrasound-guided major salivary gland C
Autor:
Ghaith Noaiseh, Alan N. Baer
Publikováno v:
Clinical Innovation in Rheumatology ISBN: 9781003207160
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90d1b759da6583404e8109876d71d495
https://doi.org/10.1201/9781003207160-7
https://doi.org/10.1201/9781003207160-7
Autor:
R. Wong, Hendrika Bootsma, Marleen Nys, Neelanjana Ray, Sumanta Mukherjee, Tsutomu Takeuchi, Raphaèle Seror, Jacques-Eric Gottenberg, Gary N. Foulks, Takayuki Sumida, E. William St. Clair, Alan N. Baer
Publikováno v:
Annals of the Rheumatic Diseases, 80(3), 339-348. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases
ObjectivesTo evaluate efficacy and safety of abatacept in adults with active primary Sjögren’s syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial.MethodsEligible patients (moderate-to-severe pSS [2016 ACR/European Le